China's biotechnology innovation lag factor
Since the implementation of "863" program, China's biotechnology research and development has developed, which not only has China's own high-tech products, but also has established technology and theoretical reserves. However, China's biotechnology, especially industrialization, has a significant gap compared to developed countries. However, in the current situation in China, there is a lot of difficulties and problems in the process of biotechnology industrialization, including:
1. Research and development investment is insufficient
Biotechnology industry is a fund-intensive industry, which is a high investment, high-risk and high-return industry. Therefore, the shortage of funds is the first problem that needs to be solved. According to statistics, the investment in the research and development of national pharmaceutical companies only accounts for 2.7% of sales, which is much lower than the average of about 15% of developed countries. During the "Ninth" period, "863" plans, national science and technology research plans, major basic research plans and natural science funds in the annual funds in biotechnology and life sciences have approximately 450 million yuan, and they are not yet as foreign companies. Annual research and development investment. This situation is not changed, and Chinese biotechnology is difficult to enter the world's advanced ranks.
2. Repeat research and development
Throughout the domestic situation, the biotechnology industry is all the fashionable industries that everyone wants. At present, the biggest troubles in the domestic business community is the repeated martial arts production, product quality, and the development of the China's modern biotechnology industry. For example, China's genetic engineering polypeptide drugs are mostly approved foreign countries that have been approved abroad or have been undergoing clinical studies, and is repeated. According to statistics, more than 30 developmental production of human granular cell-macrophage colony stimulating factor (GM-SCF), and human granular cell colony stimulus (G-CSF) have more than 30 developmental production; 13 declarations in Epokiocyte (EPO). Many manufacturers have a serious market problem. Therefore, avoid repeating research and development is the problem of China's biotechnology industrialization.
3. Industrialization process slow
China's biotechnology has relatively weak, research, development and production of instruments, equipment, etc., depending on import, small production scale, low process, low recovery, and low recovery, etc., has seriously affected the industrialization of biotechnology; again, China Most people engaged in biotechnology are scientists who study biological science basic research, lack of biotechnology industrialization expertise, to a large extent, to limit the industrialization process.
4. Industry and research
The industrialization of biotechnology requires universities, research institutes, and businesses between enterprises, and China's current state is a university, research institute office, enterprise office research institute, everyone, causing technical strength, investment repetition, funding waste. After the completion of foreign countries, after the completion of scientific research results, it is further developed, incubated, and forms a technical process after further development, incubation and formation of technical processes. In China, the two are serious, and companies who lack the scientific brains and those with technical development capabilities will transform the research into a technical process, so that scientific research and production of organic connections are detached.
5. Intellectual property awareness is weak
Due to the lack of investment in China's new drug development, intellectual property protection is weak, most biotechnology drugs currently developed and produced are mimics that have been carried out by the West, lack innovation, which will latency huge crisis. Due to high technical content of biotechnology products, there are many capital investment, and the proportion of intellectual property rights is a variety of key protection of countries. Now listed, many products are always on the threat of prosecution, and the projects that are being developed will also die because of the reasons for intellectual property. High levels of repetition, currently China's nearly 100 units engaged in genetic engineering research and development, most of them repeatedly build investment, lack of technology and market monopoly, resulting in a number of products, many sales, Competition compression, market chaos.
6. Insufficient technology innovation
